Email This Article
Headlines & Perspectives
Vertex Falls on Cystic Fibrosis Drug Study
By
Adam Feuerstein
10/20/08 - 01:03 PM EDT
Vertex's VX-770, which aims to improve function of a particular gene that is known to cause cystic fibrosis when defective, improved lung function in a clinical trial, but results were not entirely consistent with an earlier study.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,414.14 | 1,114.05 | 2,237.66 | 36.82 |
Oil *
72.73
|
|
UP
85.25
|
UP
11.58
|
UP
25.97
|
UP
1.36
|
10 Yr
3.68%
SPDR Gold
106.95
|
|
+0.83%
|
+1.05%
|
+1.17%
|
+3.84%
|
Data delayed 20 minutes |
Connect with TheStreet